1.5
CiteScore
60 days
Time to First Decision

Gout, Urate, and Crystal Deposition Disease, Volume 3, Issue 4

2025 December - 4 articles

Cover Story: It has taken longer to improve the management of calcium pyrophosphate deposition disease since its identification in the 1960s than a lifetime of a patient born at the same time to develop the disease, but progress is finally being made. The role of conventional drugs, including colchicine and methotrexate, is becoming clearer, and a better understanding of the disease’s inflammatory pathophysiology is paving the way for the use of biologics. More information on this emerging therapeutic era in CPPD disease can be found in the review published in this issue. View this paper

Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
You may sign up for email alerts to receive table of contents of newly released issues.
PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (4)

Select all

Feature Paper
Review

1,460 Views

13 Pages

The Fast-Evolving Landscape of Treatments for Calcium Pyrophosphate Deposition Disease

Vicky Tai,
Charlotte Jauffret,
Nicola Dalbeth and
Tristan Pascart

Gout Urate Cryst. Depos. Dis.2025, 3(4), 22;https://doi.org/10.3390/gucdd3040022

25 November 2025

Calcium pyrophosphate deposition (CPPD) disease is a consequence of the immune response to the pathological accumulation of calcium pyrophosphate (CPP) crystals within joints. This clinically heterogeneous condition can cause significant disability,...

Full Article

Article

1,358 Views

16 Pages

Length of Monosodium Urate Crystals in Synovial Fluid Based on Ultrasound Articular Deposits: Advancements in Crystallization Process

Elena Sansano-Muñoz,
María-del-Carmen López-González,
Cristina Rodríguez-Alvear,
Irene Calabuig,
Agustín Martínez-Sanchis,
Carlos Rodríguez-Navarro,
Eliseo Pascual and
Mariano Andrés

Gout Urate Cryst. Depos. Dis.2025, 3(4), 21;https://doi.org/10.3390/gucdd3040021

3 November 2025

Objective: Monosodium urate (MSU) crystallization in human joints is poorly understood. This study aimed to investigate whether the length of MSU crystals varies in relation to organized ultrasound deposits, which may lead to longer crystals. Methods...

Full Article

Feature Paper
Article

1,023 Views

10 Pages

Testing for Causal Association Between Serum Urate, Gout, and Prostatic Cancer in European Males

Sumanth Chandrupatla,
Nicholas Sumpter,
Riku Takei,
Tony R. Merriman and
Jasvinder Singh

Gout Urate Cryst. Depos. Dis.2025, 3(4), 20;https://doi.org/10.3390/gucdd3040020

13 October 2025

We conducted a two-sample Mendelian randomization (MR) study including only European men to test for a causal relationship between serum urate (SU), gout, and prostate cancer. Using genome-wide association (GWAS) data, we generated instrumental varia...

Full Article

Review

5,449 Views

9 Pages

Controversies in Urate-Lowering Therapy for Gout: A Comprehensive Review

Michael Toprover and
Michael H. Pillinger

Gout Urate Cryst. Depos. Dis.2025, 3(4), 19;https://doi.org/10.3390/gucdd3040019

1 October 2025

Gout is the most common inflammatory arthritis. Treatment of gout includes anti-inflammatory and urate-lowering agents. Robust guidelines by the American College of Rheumatology, the European Alliance of Associations for Rheumatology and other commit...

Full Article

Get Alerted

Add your email address to receive forthcoming issues of this journal.

Gout Urate Cryst. Depos. Dis. - ISSN 2813-4583

Imprint

Download Flyer